tbuckley/cabot-search huggingface dataset:
Brote nosocomial de escabiosis en un hospital español
Authors: A. Larrosa, M Cortés-Blanco, S. Martinez, C Clerencia, L J Urdaniz, J Urban, J Garcia
Journal: Eurosurveillance (2003)

En una sala de un hospital local de Barbastro (Huesca, Espana), se produjo un brote de escabiosis en el periodo comprendido entre noviembre de 2002 y enero de 2003. El brote se asocio a un paciente infestado de acaros, tras su ingreso en la sala el 1 de noviembre de 2002. El primer caso inicio sintomas el 5 de noviembre y el ultimo, el 5 de enero de 2003. Se declaro un total de diecisiete casos: once trabajadores sanitarios y seis pacientes. El brote se atribuyo a un retraso en el diagnostico y a la falta de medidas de proteccion individuales por parte del personal sanitario. El uso de batas de manga corta es una practica de riesgo habitual en esta sala. El contacto con fomites, animales, ropa infestada o el contacto intimo con personas que no fueran la pareja habitual quedaron descartados como factores de riesgo de infestacion. Los distintos colectivos laborales en esta sala presentaron un riesgo de infestacion similar y el mecanismo de transmision probablemente fue el contacto personal. La implantacion de pautas especificas de prevencion y tratamiento de la escabiosis, asi como un sistema de vigilancia activa, resultaron fundamentales en el control de este brote.
PRORADIUM: Prospective multicentre study of prognostic factors in castration resistant prostate cancer (CRPC) patients treated with radium-223
Authors: R. Morales Barrera, M.I. Sáez, N. Romero-Laorden, R. Lozano Mejorada, D. Lorente Estelles, G. de Velasco, M.A. Gonzalez Del Alba Baamonde, E. Gonzalez Billalabeitia, A. Medina, P. Borrega García, A. Rodriguez-Vida, U. Ferrandiz Brotons, O. Fernandez Calvo, R. García Domínguez, J. Puente, J.M. Piulats Rodriguez, R. Villatoro, E. Castro Marcos, D. Olmos Hidalgo
Journal: Annals of Oncology (2017)
Abstract 18004: Adenosine and ATPγS Protect Against Bacterial Pneumonia-Induced Acute Lung Injury
Authors: Christine M Gross, Mary L Meadows, Mary Shaw, Anita Kovacs-Kasa, Boris A Gorshkov, Alexander D Verin
Journal: Circulation (2016)

Introduction: Acute lung injury (ALI) is characterized by acute lung inflammation, increased vascular permeability, and high mortality. Sepsis associated with pneumonia from gram-negative Escherich...
Exploratory study of CK-M30 and pHH3 expression in Circulating Tumor Cells (CTCs) as biomarkers of docetaxel (DOC) efficacy in metastatic castration resistant prostate cancer (mCRPC)
Authors: P. Nombela Blanco, R. Lozano Mejorada, D. Lorente Estelles, A. Reid, N. Romero Laorden, G. Attard, Y. Cendón Flórez, J. Mateo, S. Sandhu, C. Massard, A. Montesa, P. Flohr, M.I. Sáez, M.I. Pacheco, E. Castro Marcos, J. de Bono, D. Olmos Hidalgo
Journal: Annals of Oncology (2017)
Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors.
Authors: James L. Gulley, Christopher Ryan Heery, Jeffrey Schlom, Ravi Amrit Madan, Liang Cao, Elizabeth Lamping, Jennifer L. Marte, Lisa M Cordes, Olaf Christensen, Christoph Helwig, Julius Strauss
Journal: Journal of Clinical Oncology (2017)

3006 Background: M7824 (MSB0011359C) is a novel bifunctional fusion protein comprised of a fully human IgG1 monoclonal antibody against programmed death ligand 1 (PD-L1) fused to the soluble extracellular domain of transforming growth factor-β (TGF-β) receptor II, which acts as a TGF-β trap. We report preliminary data from a phase 1 trial of M7824 in patients (pts) with advanced solid tumors. Methods: NCT02517398 is a phase 1, open-label, 3+3 dose-escalation study. Eligible pts receive M7824 at 1, 3, 10, or 20 mg/kg Q2W until confirmed progressive disease, unacceptable toxicity, or trial withdrawal; treatment beyond progression is generally allowable. The primary objective is to determine the safety and maximum tolerated dose of M7824; secondary objectives include pharmacokinetics (PK), immunogenicity, and best overall response per RECIST v1.1. Results: 16 heavily pretreated pts with ECOG performance status 0-1 have received M7824. Our PK data show a dose-linear increase in exposure starting at a dose of 3 mg/kg; furthermore, M7824 saturates peripheral PD-L1 and sequesters any released plasma TGF-β1, -β2, and -β3 throughout the dosing period in a dose-dependent manner. Grade 3 drug-related treatment-emergent adverse events (TEAEs) occurred in 3 pts (skin infection secondary to grade 2 bullous pemphigoid [BP], lipase increased, and colitis with associated anemia); there were no grade 4-5 drug-related TEAEs. BP and colitis responded well to steroids. Colitis and its secondary events of anemia and rectal hemorrhage (in a previously radiated area) were considered dose limiting in 1 pt. There was preliminary evidence of efficacy across all dose levels, including 1 ongoing confirmed complete response (cervical), 1 durable partial response (pancreatic), a 25% reduction in the sum of diameters of target lesions after 2 doses of M7824 (cervical), and 2 cases of prolonged stable disease (pancreatic; carcinoid). Conclusions: Preliminary data from this phase 1 dose-escalation study suggest that M7824 has a manageable safety profile in pts with heavily pretreated advanced solid tumors. Early signs of clinical efficacy warrant further study. Clinical trial information: NCT02517398.
<i>BRAF</i> and <i>NRAS</i> mutations in circulating Langerhans-like CD1a<sup>+</sup> cells in a patient with pulmonary Langerhans’ cell histiocytosis
Authors: Li Zhang, Gustavo Pacheco-Rodriguez, Wendy K. Steagall, Jiro Kato, Thomas V. Colby, Mary Haughey, Joel Moss
Journal: European Respiratory Journal (2017)

Pulmonary Langerhans' cell histiocytosis (PLCH) presents as accumulation of Langerhans' cells and other langerin-expressing dendritic cells (LCH cells) in the lungs that cause bilateral nodules and cavities, which are generally restricted to the upper lung fields of adult cigarette smokers [1–3]. The PLCH lung nodules appear to be the origin of the cavities, which could also have a cyst-like appearance that gives rise to a differential diagnosis that includes both cavitary and cystic lung diseases [3]. A characteristic histopathologic feature of PLCH is destruction of the wall of distal airways by infiltration of LCH cells [3]. Given the cellular aetiology, it has been proposed that LCH, and specifically PLCH, might represent a neoplastic or reactive condition [4, 5]. Currently, the diagnostic criteria of LCH include the demonstration of CD1a- and CD207-positive LCH cells in the LCH lesions [6]. As a lipid-presenting molecule, CD1a is abundantly expressed on langerin-expressing cells and accumulates in Birbeck granules, where it colocalises with langerin [6]. The BRAF mutations in LCH, including PLCH cases, were detected in 38% to 64% of LCH lesions in two independent studies [7, 8]. Recently, Mourah et al . [9] presented the remarkable finding that NRAS , in addition to BRAF mutations, occur in PLCH lesions. The findings of an abnormal cell and an oncogenic mutation are consistent with the proposal that LCH is a neoplastic disease. Detection of BRAF and NRAS in Langerhans-like cells from a patient with pulmonary Langerhans' cell histiocytosis <http://ow.ly/cCDG30f0TcT> We thank J. Philip McCoy and Leigh Samsel (both Flow Cytometry Core Facility, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA) for help with the FACS analysis.
Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration
Authors: T. Yoshino, T. Yamanaka, M. Kotaka, D. Manaka, T. Eto, J. Hasegawa, A. Takagane, M. Nakamura, T. Kato, Y. Munemoto, F. Nakamura, H. Bando, H. Taniguchi, M. Gamoh, M. Shiozawa, J. Sakamoto, S. Saji, T. Mizushima, A. Ohtsu, M. Mori
Journal: Annals of Oncology (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Authors: Yoon-Koo Kang, Narikazu Boku, Taroh Satoh, Min-Hee Ryu, Yee Chao, Ken Kato, Hyun Cheol Chung, Jen-Shi Chen, Kei Muro, Won Ki Kang, Kun-Huei Yeh, Takaki Yoshikawa, Sang Cheul Oh, Li-Yuan Bai, Takao Tamura, Keun-Wook Lee, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chin, Do-Youn Oh, Keiko Minashi, Jae Yong Cho, Masahiro Tsuda, Li-Tzong Chen
Journal: The Lancet (2017)
Component‐resolved diagnosis and beyond: Multivariable regression models to predict severity of hazelnut allergy
Authors: M. R. Datema, R. van Ree, R. Asero, L. Barreales, S. Belohlavkova, F. de Blay, M. Clausen, R. Dubakiene, C. Fernández‐Perez, P. Fritsche, D. Gislason, K. Hoffmann‐Sommergruber, M. Jedrzejczak‐Czechowicz, L. Jongejan, A. C. Knulst, M. Kowalski, T. Z. Kralimarkova, T.‐M. Le, J. Lidholm, N. G. Papadopoulos, T. A. Popov, N. del Prado, A. Purohit, I. Reig, S. L. Seneviratne, A. Sinaniotis, S. A. Versteeg, S. Vieths, A. H. Zwinderman, E. N. C. Mills, M. Fernández‐Rivas, B. Ballmer‐Weber
Journal: Allergy (2017)

Component-resolved diagnosis (CRD) has revealed significant associations between IgE against individual allergens and severity of hazelnut allergy. Less attention has been given to combining them with clinical factors in predicting severity.To analyze associations between severity and sensitization patterns, patient characteristics and clinical history, and to develop models to improve predictive accuracy.Patients reporting hazelnut allergy (n = 423) from 12 European cities were tested for IgE against individual hazelnut allergens. Symptoms (reported and during Double-blind placebo-controlled food challenge [DBPCFC]) were categorized in mild, moderate, and severe. Multiple regression models to predict severity were generated from clinical factors and sensitization patterns (CRD- and extract-based). Odds ratios (ORs) and areas under receiver-operating characteristic (ROC) curves (AUCs) were used to evaluate their predictive value.Cor a 9 and 14 were positively (OR 10.5 and 10.1, respectively), and Cor a 1 negatively (OR 0.14) associated with severe symptoms during DBPCFC, with AUCs of 0.70-073. Combining Cor a 1 and 9 improved this to 0.76. A model using a combination of atopic dermatitis (risk), pollen allergy (protection), IgE against Cor a 14 (risk) and walnut (risk) increased the AUC to 0.91. At 92% sensitivity, the specificity was 76.3%, and the positive and negative predictive values 62.2% and 95.7%, respectively. For reported symptoms, associations and generated models proved to be almost identical but weaker.A model combining CRD with clinical background and extract-based serology is superior to CRD alone in assessing the risk of severe reactions to hazelnut, particular in ruling out severe reactions.
Accepted for the impact factor – what is the impact of Eurosurveillance?
Authors: I Steffens, K Ekdahl
Journal: Eurosurveillance (2009)

Preview this article: Accepted for the impact factor – what is the impact of Eurosurveillance?, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/14/38/art19339-en-1.gif
Comparisons of outcomes of patients with advanced pancreatic cancer (APC) treated with FOLFIRINOX (FX) versus gemcitabine and nab-paclitaxel (GN): A population-based cohort study
Authors: N. Papneja, C. Olson, H. Chalchal, M. Moser, N. Iqbal, K. Haider, A. Zaidi, J. Shaw, B. Brunet, D-A. Dueck, T. Abbas, S. Ahmed
Journal: Annals of Oncology (2017)
Malária dos aeroportos uma doença rara e ainda pouco compreendida
Authors: J Mouchet
Journal: Eurosurveillance (2000)

O artigo elaborado por Daniel Lusina e colegas neste numero do Eurosurveillance (1) constitui um alerta oportuno para os perigos da malaria dos aeroportos. Desde 1977, ano em que a doenca foi pela primeira vez documentada, foram descritos 75 casos de malaria dos aeroportos na Europa ocidental, 28 dos quais ocorreram em Franca. Os doentes foram infectados na Europa, sem nunca terem estado em areas endemicas, o que levanta o problema de uma doenca rara que nao e investigada laboratorialmente de forma sistematica.
Overall Survival and Causes of Death in Neurodegeneration—An Overlooked and Underreported Theme
Authors: Filipe B. Rodrigues, Joaquim J. Ferreira
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
MRI predicts tumor grade and survival in a tv-a transgenic model of glioma
Authors: Jonathan B. Moody, Alicia R. Kreger, Patrick McConville, Erin Trachet, Richard J. Lister, William L. Elliott, W. R. Leopold, Eric C. Holland
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

1068 

INTRODUCTION: RCAS/tv-a technology relies on somatic gene transfer through infection by RCAS viral vectors derived from the avian retrovirus A (ALV-A) in mice expressing the gene for the RCAS receptor ( tv-a ). The nestin tv-a (N tv-a ) mouse, which expresses tv-a under the control of the nestin promoter in glial-progenitors, when infected with ALV virus encoding PDGF, spontaneously develops glioma by 3 weeks of age in almost 100% of cases [1]. Using this model, we correlated T2-weighted (T2w) anatomical and contrast-enhanced (CE) MRI with histology and survival in untreated mice. METHODS: 40 N tv-a mice with PDGF-induced brain tumors at 3 weeks of age, underwent weekly T2w and CE MRI, using multi-slice fast spin-echo and spin-echo sequences, respectively. In both cases, contiguous, 0.5 mm thick, transaxial slices were used to cover the entire tumor. After 4 weeks, half of the mice were sacrificed for histology, with the remaining mice kept on study for survival. RESULTS AND DISCUSSION: Tumors were well delineated in T2w images, showing features (including pseudopalisades, necrosis and cyst) that were typical of human glioblastoma multiforme (GBM) in 32% of cases (mean doubling time of 11 ± 1 days), and oligodendroglioma (mean doubling time of 19 ± 2 days) in the remaining cases. The MRI data was well correlated with histology. In GBMs only, CE MRI showed ring enhancement, and T2w images showed necrotic regions, both typical of the human condition. By a combination of initial T2w and CE MRI at 3-4 weeks age, MRI was predictive of tumor grade, and ultimately correlated with survival. CONCLUSION: The N tv-a mouse constitutes a promising model of human glioma, in which MRI is able to delineate heterogeneities due to localized regions of highly cellular tumor, necrosis, edema, cyst and abnormal vasculature, as in the human disease. MRI correlated with histology and was predictive of survival in this model. MRI methodology in the N tv-a mouse may provide an efficient preclinical means for testing novel therapies, and optimizing new combination strategies for treatment of glioma. REFERENCE: [1] Shih, et al. (2004) Cancer Res, 64, 14:4783-9
Zombie reviews taking over the PROSPERO systematic review registry. It’s time to fight back!
Authors: Renato Andrade, Rogério Pereira, Adam Weir, Clare L Ardern, João Espregueira-Mendes
Journal: British Journal of Sports Medicine (2017)

Prospective public registration of medical research is an important step to decrease the risk of duplication and reduce research waste, and increase transparency.1 2 It is a requirement for funding and publication of most clinical trials. Systematic reviews (SRs) are also important medical research—compiling original research to answer a specific research question using systematic searches, pre-established selection criteria and critically appraising and synthesising evidence to help answer a clinical question—helping clinicians make the best possible clinical decisions. Unfortunately, this cohesive advance in science is under attack. This editorial aims to highlight the current status of prospective registration of SRs and provide five useful tips.  BJSM  publishes methodological tips and pearls for conducting SRs.3 

The Centre for Reviews and Dissemination at the University of York hosts the international prospective registry platform for SRs, known as PROSPERO (https://www.crd.york.ac.uk/prospero/).4 The registry is free to use for both those registering reviews and those consulting the register. It is web-based and straightforward;,taking less than 1 hour to complete a registry entry once the author has gathered all the necessary information.5 Registering a SR involves navigating 22 mandatory and 18 optional fields that align with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.6 These fields cover the key methodological features of a SR that researchers need to consider for a good quality, clinically useful SR.7 

A SR entry is only accepted for online registration after it has been evaluated by PROSPERO. The PROSPERO evaluation focuses on the completeness of the entry and its eligibility but does not include a consideration of the quality of the …
ECDC and WHO: a common mission for better health in Europe
Authors: M Danzon
Journal: Eurosurveillance (2004)

With the opening of the European Centre for Disease Prevention and Control (ECDC) in Stockholm in May, 2005 will be an important year for public health in Europe. The idea of a European CDC has been in the air for many years, following the successful and interesting results obtained by the United States CDC in Atlanta.
PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.
Authors: Johann S. De Bono, Maha Hussain, Antoine Thiery-Vuillemin, Joaquin Mateo, A. Oliver Sartor, Kim N. Chi, Karim Fizazi, Przemyslaw Twardowski, Neeraj Agarwal, Shahneen Kaur Sandhu, David Olmos, Neal D. Shore, Fred Saad, Sherry Liu, Carsten Dietrich Goessl, Joe Burgents
Journal: Journal of Clinical Oncology (2017)

TPS5091 Background: The median overall survival for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) is short. Available agents may offer limited therapeutic benefit, but no molecularly stratified treatment has yet been approved for this heterogeneous disease. A sizable percentage of pts with mCRPC has loss of function aberrations in genes involved in homologous recombination repair (HRR) in tumor tissue, such as BRCA1/2 and ATM. These aberrations can confer sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition. A Phase II study indicated that the oral PARP inhibitor olaparib (Lynparza) had antitumor activity in 33% of mCRPC pts who had progressed after new hormonal agent (NHA) treatment and chemotherapy, with a strikingly higher composite response rate in pts with a deleterious HRR gene aberration (HRRa) (88%; 14/16) vs pts without a HRRa (6%; 2/33) (Mateo et al.2015). The PROfound study evaluates olaparib efficacy and safety versus physician’s choice of either abiraterone acetate or enzalutamide, in pts with mCRPC and a HRRa (NCT02987543). Methods: To be eligible for this multinational, open-label, Phase III study, mCRPC pts must have progressed on prior NHA treatment and have a tumor HRRa in one of 15 genes, as confirmed by an HRR Assay (Foundation Medicine, Inc.). Cohort A (n = 240 approx) includes pts with mutations in BRCA1, BRCA2 or ATM, while pts with a mutation in 12 other HRR genes will be assigned to Cohort B (n = 100 approx). Pts will be randomized (2:1) to olaparib tablets (300 mg orally bid) or physician’s choice of either enzalutamide (160 mg orally od) or abiraterone acetate (1000 mg orally od with 5 mg bid prednisone) and treatment continued until radiographic progression (as assessed by blinded independent central review) or lack of treatment tolerability. The primary endpoint of radiographic progression-free survival (rPFS) will be assessed in Cohort A using RECIST 1.1 (soft tissue) and PCWG3 (bone) criteria. Key secondary efficacy endpoints include confirmed objective response rate, time to pain progression, overall survival (all Cohort A) and rPFS (both cohorts combined). Clinical trial information: NCT02987543.
Comparison of postoperative outcomes among patients treated by male and female surgeons: a population based matched cohort study
Authors: Christopher JD Wallis, Bheeshma Ravi, Natalie Coburn, Robert K Nam, Allan S Detsky, Raj Satkunasivam
Journal: BMJ (2017)

<b>Objective</b>&nbsp;To examine the effect of surgeon sex on postoperative outcomes of patients undergoing common surgical procedures. <b>Design</b>&nbsp;Population based, retrospective, matched cohort study from 2007 to 2015. <b>Setting</b>&nbsp;Population based cohort of all patients treated in Ontario, Canada. <b>Participants</b>&nbsp;Patients undergoing one of 25 surgical procedures performed by a female surgeon were matched by patient age, patient sex, comorbidity, surgeon volume, surgeon age, and hospital to patients undergoing the same operation by a male surgeon. <b>Interventions</b>&nbsp;Sex of treating surgeon. <b>Main outcome measure</b>&nbsp;The primary outcome was a composite of death, readmission, and complications. We compared outcomes between groups using generalised estimating equations. <b>Results</b>&nbsp;104 630 patients were treated by 3314 surgeons, 774 female and 2540 male. Before matching, patients treated by female doctors were more likely to be female and younger but had similar comorbidity, income, rurality, and year of surgery. After matching, the groups were comparable. Fewer patients treated by female surgeons died, were readmitted to hospital, or had complications within 30 days (5810 of 52 315, 11.1%, 95% confidence interval 10.9% to 11.4%) than those treated by male surgeons (6046 of 52 315, 11.6%, 11.3% to 11.8%; adjusted odds ratio 0.96, 0.92 to 0.99, P=0.02). Patients treated by female surgeons were less likely to die within 30 days (adjusted odds ratio 0.88; 0.79 to 0.99, P=0.04), but there was no significant difference in readmissions or complications. Stratified analyses by patient, physician, and hospital characteristics did not significant modify the effect of surgeon sex on outcome. A retrospective analysis showed no difference in outcomes by surgeon sex in patients who had emergency surgery, where patients do not usually choose their surgeon. <b>Conclusions</b>&nbsp;After accounting for patient, surgeon, and hospital characteristics, patients treated by female surgeons had a small but statistically significant decrease in 30 day mortality and similar surgical outcomes (length of stay, complications, and readmission), compared with those treated by male surgeons. These findings support the need for further examination of the surgical outcomes and mechanisms related to physicians and the underlying processes and patterns of care to improve mortality, complications, and readmissions for all patients.